{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:29:14Z","timestamp":1795026554887,"version":"4.10.2"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.atherosclerosis.2023.117312","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T16:19:51Z","timestamp":1696090791000},"page":"117312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":201,"special_numbering":"C","title":["Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook"],"prefix":"10.1016","volume":"383","author":[{"given":"Vikrama","family":"Raja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasreen","family":"Alsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogeyaa S.","family":"Chibber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"ElBadawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Ezhov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel P.","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh Chandra","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Tokg\u00f6zoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zambon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2978-2371","authenticated-orcid":false,"given":"Jean-Pascal","family":"Berrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Farnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2023.117312_bib1","series-title":"Endotext","article-title":"Utility of advanced lipoprotein testing in clinical practice","author":"Feingold","year":"2000"},{"key":"10.1016\/j.atherosclerosis.2023.117312_bib2","doi-asserted-by":"crossref","unstructured":"P.E. Sturzebecher, J.L. Katzmann, U. Laufs, What is \u2018remnant cholesterol\u2019, Eur. Heart J. (2023). Apr 21;44(16):1446-1448.","DOI":"10.1093\/eurheartj\/ehac783"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2023.117312_bib3","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2337\/dbi19-0007","article-title":"Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease","volume":"69","author":"Chait","year":"2020","journal-title":"Diabetes"},{"issue":"18","key":"10.1016\/j.atherosclerosis.2023.117312_bib4","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1093\/eurjpc\/zwaa063","article-title":"Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions","volume":"28","author":"Welsh","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2023.117312_bib5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3343\/alm.2023.43.3.221","article-title":"Apolipoprotein B, non-HDL cholesterol, and LDL cholesterol as markers for atherosclerotic cardiovascular disease risk assessment","volume":"43","author":"Yun","year":"2023","journal-title":"Ann Lab Med"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2023.117312_bib6","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/MOL.0000000000000237","article-title":"Non-high-density lipoprotein cholesterol: current status as cardiovascular marker","volume":"26","author":"Verbeek","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"issue":"10215","key":"10.1016\/j.atherosclerosis.2023.117312_bib7","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(19)32519-X","article-title":"Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium","volume":"394","author":"Brunner","year":"2019","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.atherosclerosis.2023.117312_bib8","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1016\/j.jacc.2020.10.029","article-title":"Remnant cholesterol and atherosclerotic cardiovascular disease risk","volume":"76","author":"Burnett","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"42","key":"10.1016\/j.atherosclerosis.2023.117312_bib9","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1093\/eurheartj\/ehab531","article-title":"Keeping remnants in perspective","volume":"42","author":"Boren","year":"2021","journal-title":"Eur. Heart J."},{"issue":"42","key":"10.1016\/j.atherosclerosis.2023.117312_bib10","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1093\/eurheartj\/ehab432","article-title":"Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study","volume":"42","author":"Quispe","year":"2021","journal-title":"Eur. Heart J."},{"issue":"19","key":"10.1016\/j.atherosclerosis.2023.117312_bib11","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","year":"2001","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2023.117312_bib12","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1515\/cclm-2019-1253","article-title":"Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM","volume":"58","author":"Langlois","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"issue":"24","key":"10.1016\/j.atherosclerosis.2023.117312_bib13","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of Cardiology\/American heart association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2019","key":"10.1016\/j.atherosclerosis.2023.117312_bib14","first-page":"140","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","year":"2019","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2023.117312_bib15","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.jacc.2021.01.035","article-title":"Tracking residual risk: time for a change?","volume":"77","author":"Stone","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2023.117312_bib16","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/jamacardio.2021.5083","article-title":"Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content","volume":"7","author":"Marston","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2023.117312_bib17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1475-2840-10-20","article-title":"Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: discriminant Ratio and unbiased equivalence","volume":"10","author":"Hermans","year":"2011","journal-title":"Cardiovasc. Diabetol."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2023.117312_bib18","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/CIRCULATIONAHA.119.041149","article-title":"Comparison of conventional lipoprotein tests and apolipoproteins in the prediction of cardiovascular disease","volume":"140","author":"Welsh","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2023.117312_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/clinchem\/hvac183","article-title":"To ApoB or not to ApoB: new arguments, but basis for widespread implementation remains elusive","volume":"69","author":"Welsh","year":"2023","journal-title":"Clin. Chem."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2023.117312_bib20","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1161\/CIRCULATIONAHA.122.061188","article-title":"The lower the ApoB, the better: now, how does ApoB fit in the upcoming era of targeted therapeutics?","volume":"146","author":"Elshazly","year":"2022","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.atherosclerosis.2023.117312_bib21","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Boren","year":"2020","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2023.117312_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063346","article-title":"Pathophysiology of atherosclerosis","volume":"23","author":"Jebari-Benslaiman","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2023.117312_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1083\/jcb.201412052","article-title":"Recent insights into the cellular biology of atherosclerosis","volume":"209","author":"Tabas","year":"2015","journal-title":"J. Cell Biol."},{"issue":"47","key":"10.1016\/j.atherosclerosis.2023.117312_bib24","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.117312_bib25","doi-asserted-by":"crossref","unstructured":"O.P. Ganda, Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease, Curr. Opin. Lipidol. (2023). Jun 1;34(3):105-113.","DOI":"10.1097\/MOL.0000000000000875"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2023.117312_bib26","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2023.117312_bib27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2023.117312_bib28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s11886-015-0659-8","article-title":"Lipid-lowering drug therapy for CVD prevention: looking into the future","volume":"17","author":"Stein","year":"2015","journal-title":"Curr. Cardiol. Rep."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2023.117312_bib29","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12944-019-1080-x","article-title":"Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol","volume":"18","author":"Su","year":"2019","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.atherosclerosis.2023.117312_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1567-5688(15)30001-5","article-title":"A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: a report from an expert consensus meeting on the role of fenofibrate-statin combination therapy","volume":"19","author":"Aguiar","year":"2015","journal-title":"Atherosclerosis Suppl."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2023.117312_bib31","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2023.117312_bib32","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/ATVBAHA.119.312336","article-title":"Elevated serum non-HDL (High-Density lipoprotein) cholesterol and triglyceride levels as residual risks for myocardial infarction recurrence under statin treatment","volume":"39","author":"Suzuki","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2023.117312_bib33","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2023.117312_bib34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.atherosclerosis.2011.04.040","article-title":"Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals","volume":"218","author":"Nakamura","year":"2011","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2023.117312_bib35","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007402","article-title":"Residual risk of atherosclerotic cardiovascular events in relation to reductions in very-low-density lipoproteins","volume":"6","author":"Lawler","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2023.117312_bib36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijcard.2020.08.030","article-title":"The relation between VLDL-cholesterol and risk of cardiovascular events in patients with manifest cardiovascular disease","volume":"322","author":"Heidemann","year":"2021","journal-title":"Int. J. Cardiol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2023.117312_bib37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamacardio.2021.5080","article-title":"Apolipoprotein B vs low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as the primary measure of apolipoprotein B lipoprotein-related risk: the debate is over","volume":"7","author":"Sniderman","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"34","key":"10.1016\/j.atherosclerosis.2023.117312_bib38","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.117312_bib39","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2840-13-26","article-title":"Residual macrovascular risk in 2013: what have we learned?","volume":"13","author":"Fruchart","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"issue":"10 Suppl","key":"10.1016\/j.atherosclerosis.2023.117312_bib40","doi-asserted-by":"crossref","first-page":"1K","DOI":"10.1016\/j.amjcard.2008.10.002","article-title":"The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia","volume":"102","author":"Fruchart","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.117312_bib41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.atherosclerosis.2019.12.005","article-title":"Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM","volume":"294","author":"Nordestgaard","year":"2020","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2023.117312_bib42","doi-asserted-by":"crossref","first-page":"446","DOI":"10.4065\/mcp.2010.0058","article-title":"To B or not to B: is non-high-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B?","volume":"85","author":"Lavie","year":"2010","journal-title":"Mayo Clin. Proc."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2023.117312_bib43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11886-020-01323-z","article-title":"Non-HDL cholesterol or apoB: which to prefer as a target for the prevention of atherosclerotic cardiovascular disease?","volume":"22","author":"Langlois","year":"2020","journal-title":"Curr. Cardiol. Rep."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2023.117312_bib44","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jacl.2011.05.004","article-title":"Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement","volume":"5","author":"Contois","year":"2011","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2023.117312_bib45","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1373\/clinchem.2009.142810","article-title":"Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures","volume":"56","author":"Miller","year":"2010","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2023.117312_bib46","article-title":"Non-HDL-C is more stable than LDL-C in assessing the percent attainment of non-fasting lipid for coronary heart disease patients","volume":"8","author":"Guo","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2023.117312_bib47","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1515\/jpem-2016-0271","article-title":"Usefulness of non-fasting lipid parameters in children","volume":"30","author":"Kubo","year":"2017","journal-title":"J. Pediatr. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2023.117312_bib48","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijcard.2012.01.008","article-title":"Plasma triglyceride levels increase the risk for recurrent vascular events independent of LDL-cholesterol or nonHDL-cholesterol","volume":"167","author":"van de Woestijne","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.117312_bib49","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ijcard.2016.10.106","article-title":"Prognostic value of non-high-density lipoprotein cholesterol for mortality in patients with coronary heart disease: a systematic review and meta-analysis","volume":"227","author":"Liao","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.117312_bib50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.diabres.2015.12.002","article-title":"Comparison of lipid parameters to predict cardiovascular events in Japanese mild-to-moderate hypercholesterolemic patients with and without type 2 diabetes: subanalysis of the MEGA study","volume":"113","author":"Sone","year":"2016","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.atherosclerosis.2023.117312_bib51","doi-asserted-by":"crossref","unstructured":"Yixin Tang, Chen Chen, Hua Su, Zhenwang Tang, Jianbo Yue, Xiaotian Luo, et al., Non-HDL-C is associated with the occurrence of acute myocardial infarction in Chinese populations with diabetes, Research Square 2022) Mar 28. https:\/\/doi.org\/10.21203\/rs.3.rs-1235925\/v2.","DOI":"10.21203\/rs.3.rs-1235925\/v2"},{"key":"10.1016\/j.atherosclerosis.2023.117312_bib52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/VHRM.S95044","article-title":"Fenofibrate\/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy","volume":"13","author":"Tarantino","year":"2017","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.atherosclerosis.2023.117312_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173114","article-title":"Statins and PCSK9 inhibitors: a new lipid-lowering therapy","volume":"878","author":"Gallego-Colon","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"18_Supplement_1","key":"10.1016\/j.atherosclerosis.2023.117312_bib54","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0735-1097(21)02818-7","article-title":"Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease","volume":"77","author":"Ray","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"17","key":"10.1016\/j.atherosclerosis.2023.117312_bib55","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.jacc.2022.03.001","article-title":"Optimizing dyslipidemic cardiovascular residual risk reduction with icosapent ethyl in post-MI patients","volume":"79","author":"Boden","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2023.117312_bib56","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5551\/jat.8326","article-title":"Relationship between coronary artery disease and non-HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS)","volume":"19","author":"Sasaki","year":"2012","journal-title":"J. Atherosclerosis Thromb."},{"issue":"20","key":"10.1016\/j.atherosclerosis.2023.117312_bib57","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2023.117312_bib58","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2023.117312_bib59","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2023.117312_bib60","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.amjcard.2009.04.018","article-title":"Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial)","volume":"104","author":"Grundy","year":"2009","journal-title":"Am. J. Cardiol."},{"issue":"21","key":"10.1016\/j.atherosclerosis.2023.117312_bib61","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"7810","key":"10.1016\/j.atherosclerosis.2023.117312_bib62","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41586-020-2338-1","article-title":"Repositioning of the global epicentre of non-optimal cholesterol","volume":"582","author":"Collaboration","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2023.117312_bib63","first-page":"1","article-title":"In blood lipid profiles in 12 middle-income and high-income countries over four decades: a pooled analysis of 267 population-based measurement studies with 2\u00b73 million participants","volume":"389","author":"Trends","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2023.117312_bib64","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/jama.2019.0015","article-title":"Management of blood cholesterol","volume":"321","author":"Alenghat","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2023.117312_bib65","first-page":"24","article-title":"Clinical guidelines of the Eurasian Association of Cardiology (EAC)\/National Society for the Study of Atherosclerosis (NOA) for the diagnosis and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis (2020)","volume":"2","author":"Kukharchuk","year":"2020","journal-title":"Eurasian Cardiology Journal"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2023.117312_bib66","first-page":"8","article-title":"Lipid association of India expert consensus statement on management of dyslipidemia in Indians 2020: Part III","volume":"68","author":"Puri","year":"2020","journal-title":"J. Assoc. Phys. India"},{"key":"10.1016\/j.atherosclerosis.2023.117312_bib67","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13098-017-0251-z","article-title":"Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM)","volume":"9","author":"Bertoluci","year":"2017","journal-title":"Diabetol. Metab. Syndrome"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2023.117312_bib68","first-page":"1000","volume":"48","year":"2020","journal-title":"Zhonghua Xinxueguanbing Zazhi"},{"key":"10.1016\/j.atherosclerosis.2023.117312_bib69","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosis.2021.11.022","article-title":"Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update","volume":"343","author":"Alsayed","year":"2022","journal-title":"Atherosclerosis"},{"issue":"636","key":"10.1016\/j.atherosclerosis.2023.117312_bib70","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3399\/bjgp15X685933","article-title":"Cardiovascular risk assessment and lipid modification: NICE guideline","volume":"65","author":"Duerden","year":"2015","journal-title":"Br. J. Gen. Pract."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2023.117312_bib71","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jacl.2013.10.001","article-title":"An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia","volume":"7","author":"Expert Dyslipidemia","year":"2013","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2023.117312_bib72","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/CD9.0000000000000024","article-title":"Chinese guideline on the primary prevention of cardiovascular diseases: time to start better cardiovascular primary prevention","volume":"1","author":"Ning","year":"2021","journal-title":"Cardiology Discovery"},{"key":"10.1016\/j.atherosclerosis.2023.117312_bib73","first-page":"757","article-title":"Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention","volume":"5","author":"Millan","year":"2009","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.atherosclerosis.2023.117312_bib74","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/5931975","article-title":"Non-HDL-c\/TC: a novel lipid-related marker in the assessment of severity of coronary artery lesions and cardiovascular outcomes","volume":"2019","author":"Huang","year":"2019","journal-title":"Cardiol. Res. Pract."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915023052334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915023052334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:27:54Z","timestamp":1762187274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915023052334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":74,"alternative-id":["S0021915023052334"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.117312","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.117312","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117312"}}